Obstructive Pulmonary Diseases

1999 ◽  
pp. 185-225
Author(s):  
Henri G. Colt ◽  
Colleen J. Bergin
Keyword(s):  
Pulmonary Diseases

Artificial Intelligence Aiding the Thin-section CT Diagnosis of Diffuse Pulmonary Diseases

2006 ◽  
Vol 54 (6) ◽  
pp. 483
Author(s):  
Daehee Han ◽  
Young Hwan Koh ◽  
Chang Kyu Seong ◽  
Ji Hoon Kim ◽  
Young Ho Choi ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Thin Section ◽  
Pulmonary Diseases ◽  
Ct Diagnosis

Pulmonary Diseases: Clinicopathological Correlations

Pathology ◽  
1985 ◽  
Vol 17 (1) ◽  
pp. 141
Author(s):  
Douglas W. Henderson
Keyword(s):  
Pulmonary Diseases ◽  
Clinicopathological Correlations

Pulmonary Manifestations in Rheumatoid Arthritis, Psoriatic Arthritis and Peripheral Spondyloarthritis Prevalence, Diagnostic Approach and Treatment Options

2020 ◽  
Vol 16 ◽  
Author(s):  
Daniel Dejcman ◽  
Valentin Sebastian Schäfer ◽  
Dirk Skowasch ◽  
Carmen Pizarro ◽  
Andreas Krause ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Psoriatic Arthritis ◽  
Lung Disease ◽  
Current Knowledge ◽  
Treatment Options ◽  
Pulmonary Diseases ◽  
Chronic Obstructive ◽  
Pulmonary Manifestations ◽  
Major Cluster ◽  
Peripheral Spondyloarthritis

: Interstitial lung disease (ILD) is the most common form of pulmonary impairment in patients with rheumatoid arthritis (RA). However, patients with RA or other arthritic diseases such as psoriatic arthritis (PsA) or peripheral spondyloarthritis (pSpA) may develop several other pulmonary diseases such as chronic obstructive lung disease (COPD) with a higher risk than patients without arthritis. The article at hand aims at summarizing the current knowledge on the prevalence of pulmonary diseases in the above-mentioned forms of arthritis, the challenges for prevalence studies and detecting pulmonary diseases in patients with arthritis as well as possible treatment options. Dyspnea, cough or other pulmonary symptoms or findings in arthritis patients should prompt gradual diagnostic procedures considering pulmonary manifestations as a major cluster of differential diagnosis. Considering its poor prognosis and morbidity burden, RA-ILD needs to be ruled out. Treatment of manifestations often lacks solid evidencebased guidelines and referrals to specialized centers are often necessary.

Prospects of Gene Therapy for Pulmonary Diseases: Progress and Limitations

2017 ◽  
Vol 13 (4) ◽  
pp. 308-318 ◽  
Author(s):  
Garyfalia Karponi ◽  
Nikolaos Zogas ◽  
Kalliopi Domvri ◽  
Paul Zarogoulidis ◽  
Georgia Trakada ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Pulmonary Diseases

scholarly journals Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Alan Bénard ◽  
Anne Jacobsen ◽  
Maximilian Brunner ◽  
Christian Krautz ◽  
Bettina Klösch ◽  
...  
Keyword(s):  
Viral Load ◽  
Viral Infections ◽  
Predictive Marker ◽  
Pulmonary Diseases ◽  
Potential Therapeutic Target ◽  
Multicentric Study ◽  
Independent Prognostic Marker ◽  
Disease Marker ◽  
Infection Treatment ◽  
Innate Antiviral Immunity

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. In a prospective multicentric study, we identify IL-3 as an independent prognostic marker for the outcome during SARS-CoV-2 infections. Specifically, low plasma IL-3 levels is associated with increased severity, viral load, and mortality during SARS-CoV-2 infections. Patients with severe COVID-19 exhibit also reduced circulating plasmacytoid dendritic cells (pDCs) and low plasma IFNα and IFNλ levels when compared to non-severe COVID-19 patients. In a mouse model of pulmonary HSV-1 infection, treatment with recombinant IL-3 reduces viral load and mortality. Mechanistically, IL-3 increases innate antiviral immunity by promoting the recruitment of circulating pDCs into the airways by stimulating CXCL12 secretion from pulmonary CD123+ epithelial cells, both, in mice and in COVID-19 negative patients exhibiting pulmonary diseases. This study identifies IL-3 as a predictive disease marker for SARS-CoV-2 infections and as a potential therapeutic target for pulmunory viral infections.

Brief ICF Core Set for Obstructive Pulmonary Diseases: Validation from the Perspective of Chinese Respiratory Physicians

2021 ◽  
Vol 26 (1) ◽  
pp. 25-32
Author(s):  
Bing Liu ◽  
Pu Wang ◽  
Min Zhou ◽  
Yi Guo ◽  
Ranran Dai
Keyword(s):  
Pulmonary Diseases ◽  
Icf Core Set ◽  
Core Set
Sign in / Sign up

Export Citation Format

Share Document